The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Lenalidomide is used to treat cancer and also some anaemia disorders
The group has a total of 320 ANDA approvals
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Formulation business grew by 15 per cent in the quarter
Subscribe To Our Newsletter & Stay Updated
